Skip to main content
. 2016 Oct 10;7(5):352–369. doi: 10.5306/wjco.v7.i5.352

Table 1.

Drugs targeting phosphatidylinositol 3 kinase/Akt/mammalian target of rapamycin pathway

PI3K/Akt/mTOR subgroups Agents Clinical Stage
Pan-PI3K inhibitors XL147 Phase II
BKM120 Phase III
GDC0941 Phase II
Rapalogues (mTORC1 inhibitors) Sirolimus Phase III
Everolimus Approved
Temsirolimus Approved
Ridaforolimus Phase III
mTORC1/2 inhibitors INK128 Phase II
AZD8055 Phase I
OSI027 Phase I
PI3K–mTOR inhibitors BEZ235 Phase II
XL765 Phase II
GSK1059615 Phase I
Isoform-specific PI3K inhibitors CAL-101 (p110δ) Phase III
INK1117 (p110α) Phase I
BYL719 (p110α) Phase II
Akt inhibitors Perifosine Phase III
MK-2206 Phase II
GDC0068 Phase II
GSK690693 Phase I

PI3K: Phosphatidylinositol 3 kinase; mTOR: Mammalian target of rapamycin.